These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 27857025)
1. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. Yoo C; Kim BJ; Kim KP; Lee JL; Kim TW; Ryoo BY; Chang HM Cancer Res Treat; 2017 Jul; 49(3):759-765. PubMed ID: 27857025 [TBL] [Abstract][Full Text] [Related]
2. Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature. Busch E; Werft W; Bougatf N; Hackert T; Jäger D; Springfeld C; Berger AK Pancreas; 2021 Mar; 50(3):300-305. PubMed ID: 33835959 [TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. Seo S; Yoo C; Kim KP; Ryoo BY; Chang HM; Hong SM; Lee JH; Song KB; Hwang DW; Kim KH; Hwang S; Kim SC J Dig Dis; 2017 Aug; 18(8):480-486. PubMed ID: 28671770 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY; Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862 [TBL] [Abstract][Full Text] [Related]
5. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Moreau LC; Rajan R; Thirlwell MP; Alcindor T Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831 [TBL] [Abstract][Full Text] [Related]
6. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report. Schempf U; Sipos B; König C; Malek NP; Bitzer M; Plentz RR Z Gastroenterol; 2014 Feb; 52(2):200-3. PubMed ID: 24526405 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
9. Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens. Takahashi H; Ikeda M; Shiba S; Imaoka H; Todaka A; Shioji K; Yane K; Kojima Y; Kobayashi S; Asagi A; Ozaka M; Takada R; Nagashio Y; Horiguchi S; Kasuga A; Suzuki E; Terashima T; Ueno M; Morizane C; Furuse J Pancreas; 2021 Jan; 50(1):77-82. PubMed ID: 33370026 [TBL] [Abstract][Full Text] [Related]
10. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889 [TBL] [Abstract][Full Text] [Related]
11. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. Zaanan A; Trouilloud I; Markoutsaki T; Gauthier M; Dupont-Gossart AC; Lecomte T; Aparicio T; Artru P; Thirot-Bidault A; Joubert F; Fanica D; Taieb J BMC Cancer; 2014 Jun; 14():441. PubMed ID: 24929865 [TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. Walter T; Planchard D; Bouledrak K; Scoazec JY; Souquet PJ; Dussol AS; Guigay J; Hervieu V; Berdelou A; Ducreux M; Arpin D; Lombard-Bohas C; Baudin E Lung Cancer; 2016 Jun; 96():68-73. PubMed ID: 27133753 [TBL] [Abstract][Full Text] [Related]
14. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. Zahir MN; Jabbar AA Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487 [TBL] [Abstract][Full Text] [Related]
15. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, randomized controlled trial comparing with intravenous chemotherapy. Huang C; Cheng CS; Shen Y; Chen H; Lin J; Hua Y; Feng L; Wu C; Wang P; Chen Z; Meng Z BMC Cancer; 2024 Aug; 24(1):941. PubMed ID: 39095759 [TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related]
17. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Fogelman D; Jafari M; Varadhachary GR; Xiong H; Bullock S; Ozer H; Lin E; Morris J; Cunningham P; Bennett B; Abbruzzese JL; Wolff RA Cancer Chemother Pharmacol; 2011 Dec; 68(6):1431-8. PubMed ID: 21479635 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. Zhang L; Wang LY; Deng YM; Wang FH; Feng F; Chen YC; An X; Chen C; Xu RH; Li YH J BUON; 2011; 16(4):689-96. PubMed ID: 22331723 [TBL] [Abstract][Full Text] [Related]
20. Advancements in the management of pancreatic cancer: 2013. Saif MW JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]